Spots Global Cancer Trial Database for acute myeloid leukemia arising from previous myelodysplastic syndrome

Every month we try and update this database with for acute myeloid leukemia arising from previous myelodysplastic syndrome cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant	NCT02038153	Acute Myeloid L... Adult Acute Mye...	Laboratory Biom... Lenalidomide	60 Years - 80 Years	Albert Einstein College of Medicine
Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies	NCT01823198	Accelerated Pha... Acute Erythroid... Acute Megakaryo... Acute Myeloid L... Acute Myeloid L... Acute Myeloid L... Blast Phase Chr... Blasts Under 20... Blasts Under 20... Chronic Myelomo... High Risk Myelo... Myelodysplastic... Recurrent Chron... Therapy-Related... Therapy-Related...	Aldesleukin Allogeneic CD56... Allogeneic Hema... Busulfan Fludarabine Pho... Laboratory Biom... Peripheral Bloo... Pharmacological...	7 Years - 65 Years	M.D. Anderson Cancer Center
Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia	NCT01238211	Acute Myeloid L... Acute Myeloid L... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Core Binding Fa... Secondary Acute... Therapy-Related...	Cytarabine Dasatinib Daunorubicin Hy... Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
Fludarabine and Busulfan Followed by Allogeneic Stem Cell Transplant in Treating Older Patients With Acute Myeloid Leukemia in First Complete Remission	NCT00070135	Adult Acute Mye... Acute Myeloid L...	filgrastim Anti-Thymocyte ... busulfan fludarabine pho... methotrexate tacrolimus Allogeneic Hema...	60 Years - 74 Years	Alliance for Clinical Trials in Oncology
Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation	NCT03602898	Acute Lymphobla... Acute Myeloid L... Chronic Myelomo... Chronic Phase C... Hematopoietic a... Myelodysplastic... Myelofibrosis Myeloproliferat... Recurrent Acute... Recurrent Hodgk... Recurrent Non-H... Refractory Acut... Therapy-Related...	Anti-Thymocyte ... Busulfan Cyclophosphamid... Cyclosporine Fludarabine Pho... Methotrexate Peripheral Bloo... Quality-of-Life... Questionnaire A... Tacrolimus Total-Body Irra...	- 65 Years	Fred Hutchinson Cancer Center
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission	NCT00093470	Acute Myeloid L... Adult Acute Meg... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Alkylating Agen... Myelodysplastic... Recurrent Adult...	Clinical Observ... Tipifarnib	18 Years -	National Cancer Institute (NCI)
Avelumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia	NCT02953561	Acute Myeloid L... Recurrent Acute... Refractory Acut...	Avelumab Azacitidine Laboratory Biom...	18 Years -	M.D. Anderson Cancer Center
BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia	NCT04284787	Acute Myeloid L... Acute Myeloid L... Acute Myeloid L... Secondary Acute...	Azacitidine Biopsy Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Pembrolizumab Venetoclax	60 Years -	National Cancer Institute (NCI)
Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia	NCT00392353	Acute Erythroid... Acute Megakaryo... Acute Myeloid L... Chronic Myelomo... Myelodysplastic... Myelodysplastic... Myelodysplastic... Recurrent Adult... Refractory Anem...	Azacitidine Laboratory Biom... Pharmacological... Vorinostat	18 Years -	National Cancer Institute (NCI)
Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome	NCT03813147	Acute Myeloid L... Recurrent Acute... Recurrent Myelo... Refractory Acut... Refractory Myel...	Azacitidine Cytarabine Fludarabine Pho... Methotrexate Pevonedistat Therapeutic Hyd...	1 Month - 21 Years	National Cancer Institute (NCI)
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome	NCT03670966	Acute Lymphobla... Acute Myeloid L... Acute Myeloid L... Chronic Myelomo... Myelodysplastic... Recurrent Acute... Recurrent Acute... Refractory Acut... Refractory Acut... Recurrent Mixed... Refractory Mixe... Hematopoietic a...	Astatine At 211... Cyclophosphamid... Total-Body Irra... Peripheral Bloo... Bone Marrow Tra... Mycophenolate M... Recombinant Gra... Fludarabine Pho... Tacrolimus Bone Marrow Asp... Biospecimen Col...	18 Years - 75 Years	Fred Hutchinson Cancer Center
CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia	NCT02286726	Acute Myeloid L... Acute Myeloid L... Secondary Acute...	Laboratory Biom... Liposome-encaps...	18 Years -	M.D. Anderson Cancer Center
CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old	NCT04269213	Acute Myeloid L... Acute Myeloid L... Secondary Acute... Therapy-Related...	Liposome-encaps...	18 Years - 59 Years	Roswell Park Cancer Institute
BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia	NCT04214249	Acute Myeloid L... Acute Myeloid L... Acute Myeloid L... Secondary Acute...	Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Cytarabine Daunorubicin Hy... Echocardiograph... Hematopoietic C... Idarubicin Hydr... Multigated Acqu... Pembrolizumab Punch Biopsy	18 Years - 75 Years	National Cancer Institute (NCI)
Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia	NCT01885689	Adult Acute Lym... Acute Myeloid L... Adult Acute Mye... Myelodysplastic... Secondary Myelo... Chronic Myelomo... Therapy-Related...	clofarabine melphalan allogeneic hema... tacrolimus sirolimus Pharmacological...	18 Years - 75 Years	City of Hope Medical Center
Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia	NCT00313586	Acute Myeloid L... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Pro... Alkylating Agen... Chronic Myelomo... de Novo Myelody... Previously Trea... Recurrent Adult... Secondary Acute... Secondary Myelo... Untreated Adult...	Azacitidine Entinostat Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
Ruxolitinib and Venetoclax in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	NCT03874052	Acute Myeloid L... Recurrent Acute... Refractory Acut...	Ruxolitinib Venetoclax	18 Years -	OHSU Knight Cancer Institute
Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia	NCT01904136	Accelerated Pha... Acute Myeloid L... Acute Myeloid L... Blast Phase Chr... de Novo Myelody... Myelodysplastic... Recurrent Acute... Recurrent Chron... Therapy-Related...	Allogeneic Hema... Bone Marrow Tra... Cyclophosphamid... Fludarabine Laboratory Biom... Melphalan Mycophenolate M... Natural Killer ... Peripheral Bloo... Tacrolimus Total-Body Irra...	2 Years - 65 Years	M.D. Anderson Cancer Center
Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma	NCT03096782	Accelerated Pha... Acute Biphenoty... Acute Leukemia Acute Lymphobla... Acute Lymphobla... Acute Myeloid L... Acute Myeloid L... Chemotherapy-Re... Chronic Lymphoc... Chronic Myeloge... Chronic Myelomo... Hodgkin Lymphom... Langerhans Cell... Minimal Residua... Myelodysplastic... Myelodysplastic... Non-Hodgkin Lym... Recurrent Hodgk... Refractory Acut... Refractory Myel... Small Lymphocyt... Therapy-Related...	Anti-Thymocyte ... Busulfan Clofarabine Cyclophosphamid... Filgrastim-sndz Fludarabine Melphalan Mycophenolate M... Rituximab Tacrolimus Total-Body Irra... Umbilical Cord ...	12 Years - 65 Years	M.D. Anderson Cancer Center
Veliparib and Temozolomide in Treating Patients With Acute Leukemia	NCT01139970	Acute Lymphobla... Acute Myeloid L... Acute Myeloid L... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Pro... Adult B Acute L... Adult B Acute L... Adult T Acute L... Alkylating Agen... Chronic Myelomo... Recurrent Adult... Recurrent Adult... Secondary Acute...	Laboratory Biom... Pharmacological... Temozolomide Veliparib	18 Years -	National Cancer Institute (NCI)
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission	NCT00093470	Acute Myeloid L... Adult Acute Meg... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Alkylating Agen... Myelodysplastic... Recurrent Adult...	Clinical Observ... Tipifarnib	18 Years -	National Cancer Institute (NCI)
Fludarabine and Busulfan Followed by Allogeneic Stem Cell Transplant in Treating Older Patients With Acute Myeloid Leukemia in First Complete Remission	NCT00070135	Adult Acute Mye... Acute Myeloid L...	filgrastim Anti-Thymocyte ... busulfan fludarabine pho... methotrexate tacrolimus Allogeneic Hema...	60 Years - 74 Years	Alliance for Clinical Trials in Oncology
Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia	NCT02397720	Acute Bilineal ... Acute Biphenoty... Acute Myeloid L... Chronic Myelomo... Myelodysplastic... Recurrent Acute... Refractory Acut... Secondary Acute... Therapy-Related...	Azacitidine Ipilimumab Laboratory Biom... Nivolumab	18 Years -	M.D. Anderson Cancer Center
CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old	NCT04269213	Acute Myeloid L... Acute Myeloid L... Secondary Acute... Therapy-Related...	Liposome-encaps...	18 Years - 59 Years	Roswell Park Cancer Institute
Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia	NCT01420926	Acute Myeloid L... Acute Myeloid L... Therapy-Related...	Bortezomib Decitabine Laboratory Biom... Pharmacological... Quality-of-Life... Questionnaire A...	60 Years -	National Cancer Institute (NCI)
Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia	NCT01757639	Acute Myeloid L... Chronic Myelomo... Myelodysplastic... Previously Trea... Recurrent Adult... Secondary Myelo...	Ipilimumab Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia	NCT01885689	Adult Acute Lym... Acute Myeloid L... Adult Acute Mye... Myelodysplastic... Secondary Myelo... Chronic Myelomo... Therapy-Related...	clofarabine melphalan allogeneic hema... tacrolimus sirolimus Pharmacological...	18 Years - 75 Years	City of Hope Medical Center
Cognitive Behavioral Therapy in Helping Patients With Acute Myeloid Leukemia or Lymphoma With Cancer-Related Fatigue	NCT03747757	Acute Myeloid L... Acute Myeloid L... Cancer Fatigue Lymphoma Secondary Acute...	Cognitive Behav... Quality-of-Life... Questionnaire A...	18 Years -	M.D. Anderson Cancer Center
Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent	NCT03146871	Acute Myeloid L... Chronic Myelomo... Previously Trea... Recurrent Acute... Recurrent Adult...	Azacitidine Decitabine Laboratory Biom... Pharmacological... Recombinant Eph...	18 Years -	University of Southern California
Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation	NCT03953898	Acute Myeloid L... Acute Myeloid L... Acute Myeloid L... Recurrent Acute... Recurrent Myelo... Refractory Acut... Refractory Myel...	Biospecimen Col... Bone Marrow Asp... Olaparib	18 Years -	National Cancer Institute (NCI)
Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia	NCT00313586	Acute Myeloid L... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Pro... Alkylating Agen... Chronic Myelomo... de Novo Myelody... Previously Trea... Recurrent Adult... Secondary Acute... Secondary Myelo... Untreated Adult...	Azacitidine Entinostat Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia	NCT03128034	Acute Lymphobla... Acute Myeloid L... Acute Myeloid L... Chronic Myelomo... Myelodysplastic... Recurrent Acute... Refractory Acut... Recurrent Acute... Recurrent Mixed... Refractory Acut... Refractory Mixe... Mixed Phenotype...	Cyclosporine Fludarabine Pho... Laboratory Biom... Mycophenolate M... Peripheral Bloo... Pharmacological... Pretargeted Rad... Total-Body Irra...	18 Years - 75 Years	Fred Hutchinson Cancer Center
Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome	NCT03672539	Acute Myeloid L... Chronic Myelomo... High Risk Myelo... Myelodysplastic... Recurrent Acute... Refractory Acut...	Gemtuzumab Ozog... Liposome-encaps... Quality-of-Life...	18 Years -	M.D. Anderson Cancer Center
CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia	NCT02286726	Acute Myeloid L... Acute Myeloid L... Secondary Acute...	Laboratory Biom... Liposome-encaps...	18 Years -	M.D. Anderson Cancer Center
Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent	NCT03146871	Acute Myeloid L... Chronic Myelomo... Previously Trea... Recurrent Acute... Recurrent Adult...	Azacitidine Decitabine Laboratory Biom... Pharmacological... Recombinant Eph...	18 Years -	University of Southern California
Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	NCT01664897	Acute Myeloid L... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Pro... Alkylating Agen... Chronic Myelomo... Myelodysplastic... Previously Trea... Recurrent Adult...	Erlotinib Hydro... Laboratory Biom...	18 Years -	M.D. Anderson Cancer Center
Veliparib and Temozolomide in Treating Patients With Acute Leukemia	NCT01139970	Acute Lymphobla... Acute Myeloid L... Acute Myeloid L... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Pro... Adult B Acute L... Adult B Acute L... Adult T Acute L... Alkylating Agen... Chronic Myelomo... Recurrent Adult... Recurrent Adult... Secondary Acute...	Laboratory Biom... Pharmacological... Temozolomide Veliparib	18 Years -	National Cancer Institute (NCI)
Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome	NCT03404193	Acute Myeloid L... Acute Myeloid L... Blastic Plasmac... Chronic Myelomo... Mixed Phenotype... Myelodysplastic... Recurrent Acute... Recurrent Acute... Recurrent Blast... Recurrent Chron... Recurrent Mixed... Refractory Acut... Refractory Blas... Refractory Chro... Refractory Mixe...	Decitabine Laboratory Biom... Venetoclax	18 Years -	M.D. Anderson Cancer Center
Veliparib and Temozolomide in Treating Patients With Acute Leukemia	NCT01139970	Acute Lymphobla... Acute Myeloid L... Acute Myeloid L... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Pro... Adult B Acute L... Adult B Acute L... Adult T Acute L... Alkylating Agen... Chronic Myelomo... Recurrent Adult... Recurrent Adult... Secondary Acute...	Laboratory Biom... Pharmacological... Temozolomide Veliparib	18 Years -	National Cancer Institute (NCI)
Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia	NCT01757639	Acute Myeloid L... Chronic Myelomo... Myelodysplastic... Previously Trea... Recurrent Adult... Secondary Myelo...	Ipilimumab Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
Lirilumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia	NCT02399917	Acute Biphenoty... Acute Myeloid L... Recurrent Acute... Refractory Acut...	Azacitidine Lirilumab	18 Years -	M.D. Anderson Cancer Center
Nivolumab in AML in Remission at High Risk for Relapse	NCT02532231	Acute Myeloid L... Adult Acute Mye... Blasts Under 10... Therapy-Related...	Laboratory Biom... Nivolumab	18 Years -	M.D. Anderson Cancer Center
Avelumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia	NCT02953561	Acute Myeloid L... Recurrent Acute... Refractory Acut...	Avelumab Azacitidine Laboratory Biom...	18 Years -	M.D. Anderson Cancer Center
Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia	NCT01904136	Accelerated Pha... Acute Myeloid L... Acute Myeloid L... Blast Phase Chr... de Novo Myelody... Myelodysplastic... Recurrent Acute... Recurrent Chron... Therapy-Related...	Allogeneic Hema... Bone Marrow Tra... Cyclophosphamid... Fludarabine Laboratory Biom... Melphalan Mycophenolate M... Natural Killer ... Peripheral Bloo... Tacrolimus Total-Body Irra...	2 Years - 65 Years	M.D. Anderson Cancer Center
Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation	NCT03602898	Acute Lymphobla... Acute Myeloid L... Chronic Myelomo... Chronic Phase C... Hematopoietic a... Myelodysplastic... Myelofibrosis Myeloproliferat... Recurrent Acute... Recurrent Hodgk... Recurrent Non-H... Refractory Acut... Therapy-Related...	Anti-Thymocyte ... Busulfan Cyclophosphamid... Cyclosporine Fludarabine Pho... Methotrexate Peripheral Bloo... Quality-of-Life... Questionnaire A... Tacrolimus Total-Body Irra...	- 65 Years	Fred Hutchinson Cancer Center
Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia	NCT03330821	Acute Myeloid L... Acute Myeloid L... Therapy-Related...	Cytarabine Idarubicin Laboratory Biom... Pevonedistat Pharmacological...	18 Years -	University of Southern California
Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia	NCT02658487	Acute Myeloid L... Acute Myeloid L... Acute Myeloid L... Myeloid Sarcoma Secondary Acute... Therapy-Related... Therapy-Related...	Cytarabine Vosaroxin	18 Years -	Vanderbilt-Ingram Cancer Center

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: